Core Insights - electroCore reported record net sales of $32.0 million for the full year 2025, representing a 27% increase from $25.2 million in 2024, driven by a 25% growth in the U.S. prescription business and a 97% increase in general wellness sales [1][2][7] Financial Performance - The increase in net sales of $6.8 million was primarily due to higher sales of prescription products gammaCore and Quell Fibromyalgia in the U.S., as well as Truvaga handsets in the general wellness channel [2] - Gross profit rose by $6.4 million to $27.8 million in 2025, with a gross margin of 87%, up from 85% in 2024 [3] - Research and development expenses increased to $2.7 million, up by $0.4 million from the previous year, mainly due to development costs for gammaCore Emerald and a new mobile application [4] - Selling, general, and administrative expenses totaled $38.2 million, an increase of $7.0 million from $31.2 million in 2024, driven by higher sales and marketing costs [5] - Total operating expenses for 2025 were approximately $40.9 million, compared to $33.6 million in 2024 [6] Loss and Cash Position - The GAAP net loss for 2025 was $14.0 million, compared to a loss of $11.9 million in 2024, with a net loss per share of $1.65 [9][21] - Total cash, cash equivalents, and marketable securities amounted to $11.6 million at the end of 2025, down from $12.2 million at the end of 2024 [11] Future Guidance - The company provided revenue guidance for 2026, anticipating approximately 30% annual growth over 2025 [12] Organizational Changes - Dan Goldberger, the CEO, will retire effective April 1, 2026, with Joshua Lev taking on the role of interim President and CFO, and Michael Fox joining as Chief Operating Officer [13][14]

Company Overview - electroCore, Inc. is a bioelectronic medicine and wellness company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [4] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for chronic pain syndromes, and Quell Fibromyalgia [4] - electroCore also offers handheld products like Trvuaga and TAC-STIM nVNS for general wellness and human performance [4] Event Participation - Management will participate in the 38th Annual Roth Conference from March 22-24, 2026, at the Ritz-Carlton in Laguna Niguel, California [1] - Joshua Lev, the Chief Financial Officer, will host one-on-one meetings during the conference [1] - Investors interested in scheduling meetings can contact their Roth representative or email investors@electrocore.com for more information [2] Conference Details - The Annual Roth Conference is one of the largest in the nation for small-cap companies, featuring company presentations, Q&A sessions, and management one-on-one meetings [3] - Approximately 500 private and public companies from various growth sectors will be represented at the conference [3] - Roth's Research Team identifies distinguished presenting companies across sectors such as consumer, energy, healthcare, industrial growth, metals & mining, sustainability, services, and technology [3]

Core Insights - electroCore, Inc. anticipates record revenue for full year 2025 of approximately $31.8 - $32.0 million, representing a growth of about 26% compared to 2024 revenue of $25.2 million [2][7] - For the fourth quarter of 2025, the company expects revenue to be approximately $9.0 - $9.2 million, indicating a growth of around 30% over the fourth quarter of 2024 [2][7] - The company's total cash position at the end of 2025 is approximately $11.6 million, down from approximately $13.2 million as of September 30, 2025 [3][7] Financial Guidance - Full year 2025 revenue is projected to be between $31.8 million and $32.0 million, marking a 26% increase from 2024 [2][7] - Fourth quarter 2025 revenue is expected to be between $9.0 million and $9.2 million, reflecting a 30% increase from the same quarter in 2024 [2][7] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [4] - The company's leading products include gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, which address chronic pain syndromes [4]

Core Insights - electroCore, Inc. is participating in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York [1] - The company will host one-on-one meetings throughout the day for investors [1][2] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device for chronic pain, and Quell Fibromyalgia [3] - Additionally, electroCore offers handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Insights - electroCore, Inc. reported net sales of $8.7 million for Q3 2025, a 33% increase compared to Q3 2024, and year-to-date net sales of $22.8 million, reflecting a 26% increase compared to the first nine months of 2024 [1][3][8] - The company has increased its revenue guidance for the full year 2025 to a range of $31.5 million to $32.5 million, driven by strong sales growth in the VA market for its prescription products [2][14] Financial Performance - For Q3 2025, net sales were $8.7 million, up from $6.6 million in Q3 2024, with a gross profit of $7.5 million, representing an 86% gross margin compared to 84% in the previous year [3][4][10] - Prescription device sales increased by 19% year-over-year, while health and wellness products saw a significant growth of 121% in the same period [4][8] - Total operating expenses for Q3 2025 were approximately $10.4 million, up from $8.1 million in Q3 2024, with selling, general, and administrative expenses rising to $9.7 million [6][7] Cash Position - As of September 30, 2025, total cash, including cash equivalents and marketable securities, was $13.2 million, an increase from $12.2 million at the end of 2024 [1][13][22] Loss and Adjusted EBITDA - The net loss for Q3 2025 was $3.4 million, or $0.40 per share, compared to a net loss of $2.5 million, or $0.31 per share, in Q3 2024 [10][20] - Adjusted EBITDA net loss for Q3 2025 was $2.0 million, slightly improved from a loss of $2.1 million in Q3 2024 [11][26] Future Outlook - The company anticipates reaching $12.0 million in quarterly revenue and achieving its first quarter of positive adjusted EBITDA in the second half of 2026 [14]